Skip to content
Niva Bupa Health Insurance Company logo

Niva Bupa Health Insurance Company

NIVABUPA NSE
₹74.36 +0.36 (+0.49%)
Market Cap
₹13,754 Cr
P/E
39.76
View as Markdown
MCP
Close 20 Nov 2026 ₹74.36 1Y +0.09 +0.12%
Start ₹74.27

Key Fundamentals

MicrocapInsuranceFinancial Services

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
3.15%
Debt to Equity
0.07
EPS (TTM)
₹1.87
Book Value
₹20.78
Market Cap
₹13,754 Cr
P/E (TTM)
39.76
P/B
3.58
ROE
3.46%
Dividend Yield
0.00%
EBITDA
₹163 Cr
52W High
₹91.40
52W Low
₹67.50
Day Range
₹73.13 – ₹74.50
Volume
4,76,069

Peer Comparison

Financial Services › Insurance › General Insurance

Niva Bupa Health Insurance Company peer comparison
1,736.0033.9086,7334.610.43%16.60%21.90%29,0382,555
332.306.5058,2990.793.91%14.60%17.40%54,9938,969
556.0531.0532,7303.140.00%7.61%9.69%20,0561,054
152.63—25,1530.891.00%4.92%4.29%50,234−528
239.0027.2522,1112.720.00%12.20%13.10%11,994810
74.3639.7613,7543.580.00%3.46%3.15%8,905345
Median 6 companies285.6531.0528,9422.930.22%9.91%11.40%24,547932

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

44 Weak

Data confidence 97/100

Category scores

Quality
32
Poor
Returns, margins, earnings quality 22% weight
Valuation
37
Poor
Cheap vs sector & own history 24% weight
Growth
84
Strong
Sales & profit trajectory 9% weight
Financial Health
27
Poor
Solvency, leverage, coverage 9% weight
Momentum
19
Poor
Trend strength, vol-adjusted 12% weight
Ownership
59
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has delivered good profit growth of 35.9% CAGR over last 5 years

Weaknesses

3
  • Stock is trading at 3.58 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 5.20% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1261
OscillatorsBearish261
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
45.18
Neutral
MACD (12,26,9)
−0.23
Bearish
SMA (50)
76.37
Bearish
SMA (200)
79.38
Bearish

As of

Analyst Rating

Based on 10 analysts
BUY90%

9 of 10 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
9
90%
HOLD
1
10%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
5Y+36.50%
3Y+32.89%
1Y+24.58%
TTM+28.87%

Net profit

Net profit growth by window
5YTurned to profit
3Y+115.99%
1Y−38.79%
TTM−1.71%

Operating cash flow

Operating cash flow growth by window
5Y+28.63%
3Y+15.13%
1Y−45.28%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y+3.95 pp
3Y+13.96 pp
1Y+0.85 pp
TTM−0.78 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2019₹851 Cr
Mar 2020₹1,057 Cr
Mar 2021₹1,413 Cr
Mar 2022₹1,877 Cr
Mar 2023₹2,853 Cr
Mar 2024₹4,115 Cr
Mar 2025₹5,374 Cr
Mar 2026₹6,695 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2019−₹48.00 Cr
Mar 2020−₹62.00 Cr
Mar 2021−₹50.00 Cr
Mar 2022−₹197 Cr
Mar 2023₹13.00 Cr
Mar 2024₹82.00 Cr
Mar 2025₹214 Cr
Mar 2026₹131 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹705 Cr +333.8% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 19 Nov 2026
AI opinion · based on fundamentals
Risk high

Niva Bupa Health Insurance trades at ₹74 per share as of 2026-11-19 with a market cap of ₹13,687 crore. The company has demonstrated strong compounded sales growth of 33% over 3 years and 36% over 5 years, but profitability metrics remain modest with a 3-year average ROE of 5% and a trailing twelve-month PE of 39.57x. The stock is down roughly 19% from its 52-week high of ₹91.4.

Bull Case 6
  • The company is virtually debt free with a debt-to-equity ratio of just 0.07, providing significant financial flexibility and resilience against adverse market conditions.
  • Compounded sales growth stands at 33% over 3 years and 36% over 5 years, reflecting strong and sustained top-line momentum in a structurally underpenetrated health insurance market.
  • Compounded profit growth of 127% over 3 years indicates a sharp improvement in the company's ability to convert revenue growth into bottom-line gains.
  • 5-year compounded profit CAGR of 35.9% demonstrates consistent long-term earnings expansion well above broader market growth rates.
  • TTM revenue growth of 29% shows the company continues to scale at a healthy pace even on a larger base.
  • India's health insurance penetration remains low relative to global peers, providing a long structural growth runway for established players in the sector.
Bear Case 7
  • The stock trades at 3.56 times book value, which is rich for a company generating a return on equity of only 3.45% on a trailing basis.
  • Return on equity has been consistently low at 5% over 3 years, 3% over 5 years, and 3% in the last year, indicating the company is not generating strong returns on shareholders' capital.
  • ROCE stands at -2.9%, suggesting the company's overall capital deployment is currently not generating positive returns when considering total capital employed.
  • Despite reporting repeated profits, the company pays zero dividend (0% yield), returning no cash to shareholders.
  • TTM profit growth has turned negative at -2%, signalling a potential deceleration or margin compression after a period of rapid earnings expansion.
  • The 1-year stock CAGR of -4% indicates the market has de-rated the stock over the past year, reflecting waning investor sentiment.
  • EPS of ₹1.87 on a share price of ₹74 implies investors are paying a steep premium per rupee of current earnings, amplifying downside risk if growth disappoints.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

23h ago

TL;DR: Niva Bupa is on a strong growth trajectory with Q2FY27 net profit doubling and revenue up 27% YoY on robust premium momentum. The launch of Meridian and early NCD redemption reflect product expansion and balance-sheet discipline. No material headwinds emerged in the period. Key to watch is whether premium growth sustains through H2FY27 and whether the expanded ESOP pool leads to meaningful dilution.

Positives 3
  • Q2 net profit doubles YoY Nov 4

    Niva Bupa posted net profit of ₹13.56 crore in Q2FY27, up 124% YoY. Revenue rose 27% to ₹241.23 crore on strong premium growth.

  • Meridian product launched Nov 18

    Niva Bupa launched Meridian on November 18, 2026, a health insurance product offering both domestic and international coverage, broadening its product suite.

  • ₹150 crore NCD redemption Nov 13

    Completed full redemption of ₹150 crore non-convertible debentures via call option on November 13, 2026, reducing debt on the balance sheet.

Neutral 3
  • ESOP pool doubling proposed Nov 17

    Niva Bupa proposes adding 3.90 crore options to raise the ESOP 2024 pool to 7.72 crore. Shareholder voting runs November 19 to December 18, 2026.

  • Investor conference participation Nov 10

    Niva Bupa will participate in investor conferences in Mumbai on November 17 and 18, 2026, signalling active engagement with the investment community.

  • UPSI policies consolidated Nov 4

    Board approved merging its Fair Disclosure and Leak Inquiry policies into a single document under SEBI guidelines, a routine governance update.

Quarterly Results

₹ Cr
NIVABUPA quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
969
1,026
1,316
1,124
1,321
1,258
1,671
1,932
2,049
1,611
2,251
2,471
2,572
Expenses
1,027
1,071
1,215
1,228
1,387
1,282
1,420
1,834
1,967
1,705
2,069
2,287
2,389
Operating Profit
−58
−46
100
−103
−66
−24
251
98
82
−94
182
184
183
OPM %
−6%
−4.4%
8%
−9%
−5%
−1.9%
15%
5%
4%
−6%
8%
7%
7%
Other Income
50
50
57
84
79
37
−45
0
0
7
−1
0
−2
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
−8
5
157
−19
13
13
206
98
82
−88
181
184
182
Tax %
0%
0%
0%
0%
0%
0%
0%
27%
26%
0%
12%
25%
25%
Net Profit
−8
5
157
−19
13
13
206
71
61
−88
159
138
136
EPS (₹)
—
—
—
—
—
0.07
1.13
0.39
0.33
−0.47
0.86
0.75
0.73
YoY Sales growth
—
—
—
—
36
23
27
72
55
28
35
28
26

Profit & Loss

₹ Cr
NIVABUPA profit and loss, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
851
1,057
1,413
1,877
2,853
4,115
5,374
6,695
8,905
Expenses
880
1,094
1,435
2,328
3,183
4,228
5,292
6,534
8,450
Operating Profit
−29
−37
−22
−451
−330
−113
83
160
455
OPM %
−3.4%
−3.5%
−1.5%
−24%
−12%
−2.7%
1.5%
2.4%
5%
Other Income
0
0
0
281
374
224
155
1.34
3
Interest
3
4
6
0
0
0
0
0
0
Depreciation
16
21
22
27
32
29
25
36
0
PBT
−48
−62
−50
−197
13
82
214
127
458
Tax %
0%
0%
0%
0%
0%
0%
0%
−3%
—
Net Profit
−48
−62
−50
−197
13
82
214
131
345
EPS (₹)
—
—
—
—
—
—
1.17
0.71
1.87
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
—
Sales growth
—
24
34
33
52
44
31
25
29

Balance Sheet

₹ Cr
NIVABUPA balance sheet, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
981
1,126
1,350
1,409
1,511
1,700
1,827
1,847
1,850
Reserves
−719
−780
−773
−903
−683
351
1,949
1,939
1,994
Borrowings
0
0
0
250
250
250
250
250
268
Other Liabilities
737
891
1,322
1,983
2,799
3,891
5,735
7,240
8,017
Total Liabilities
1,000
1,237
1,899
2,738
3,877
6,192
9,760
11,276
12,128
Fixed Assets
30
39
46
49
52
58
66
85
180
CWIP
2
2
2
1
4
1
9
3
0
Investments
816
1,067
1,622
2,401
3,366
5,458
8,175
9,670
10,659
Other Assets
152
129
230
287
455
675
1,510
1,518
1,288
Total Assets
1,000
1,237
1,899
2,738
3,877
6,192
9,760
11,276
12,128

Cash Flow

₹ Cr
NIVABUPA cash flow, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
—
—
257
338
593
813
1,654
905
Investing
—
—
−374
−723
−829
−1,882
−2,348
−961
Financing
—
—
280
374
280
1,110
771
−5
Net Cash Flow
—
—
164
−12
43
41
78
−62
Free Cash Flow
—
—
229
309
555
780
1,614
857
CFO/EBITDA
—
—
−1,180
−75
−180
−720
2,000
577

Ratios

NIVABUPA financial ratios, annual
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
0
0
0
0
0
0
0
0
Cash Conversion Cycle
0
0
0
0
0
0
0
0
Working Capital Days
−264
−270
−290
−341
−313
−298
−351
−354
ROCE %
—
−19%
−10%
−30%
1%
5%
7%
3%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Niva Bupa Health Insurance Company insights

31 extracted metrics across FY19–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 55.29%
  • DIIs 15.89%
  • FIIs 12.95%
  • Others 12.06%
  • Public 3.81%

No promoter shares pledged as of 14 Oct 2026

Change since Jun 2026

Documents

Frequently Asked Questions about Niva Bupa Health Insurance Company

What does Niva Bupa Health Insurance Company Ltd do?
Incorporated in 2008, Niva Bupa Health Insurance Ltd is a Tech driven leading health insurer in India.
Where is Niva Bupa Health Insurance Company Ltd (NIVABUPA) listed?
Niva Bupa Health Insurance Company Ltd trades as NIVABUPA on the NSE and under code 544286 on the BSE.
Which sector does Niva Bupa Health Insurance Company Ltd belong to?
Niva Bupa Health Insurance Company Ltd is classified under the Financial Services sector, in the Insurance industry.
What is the market capitalisation of Niva Bupa Health Insurance Company Ltd?
Niva Bupa Health Insurance Company Ltd has a market capitalisation of ₹13,754 Cr as of 20 Nov 2026, which places it in the Microcap band.
What is the PE ratio of Niva Bupa Health Insurance Company Ltd?
Niva Bupa Health Insurance Company Ltd trades at a PE ratio of 39.76 as of 20 Nov 2026, on earnings per share of ₹1.87, against a book value of ₹20.78 per share.
What is the 52-week high and low of Niva Bupa Health Insurance Company Ltd?
Over the last 52 weeks Niva Bupa Health Insurance Company Ltd has traded between ₹67.5 and ₹91.4 as of 20 Nov 2026.
What is the Return on Equity (ROE) of Niva Bupa Health Insurance Company Ltd?
Niva Bupa Health Insurance Company Ltd reported a return on equity of 3.46%. Its debt-to-equity ratio is 0.07.

Company Information

Incorporated in 2008, Niva Bupa Health Insurance Ltd is a Tech driven leading health insurer in India.

Website nivabupa.com
Listed 14 Nov 2024
Face Value ₹10
Shares Outstanding 1,84,96,44,703

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NIVABUPA.md for Niva Bupa Health Insurance Company Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More